BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.

This report comes at a time of tremendous growth for BeiGene. In 2023, the Company achieved the milestone of more than 1 million patients who were treated worldwide with BTK inhibitor BRUKINSA (zanubrutinib) and anti-PD-1 antibody TEVIMBRA (tislelizumab). The Company is also actively expanding its presence globally, including in the U.S., where it expects to open a flagship research and development and manufacturing facility at the Princeton West Innovation Campus in Hopewell, New Jersey, in July.

“All patients with cancer deserve access to high-quality, impactful medicines regardless of their location or socioeconomic status, but many wait years to access, or simply cannot afford, innovative treatment options. Our founding belief is that there is a better way to lower these barriers and broaden our reach and impact, which is why we’ve strategically built our company to bring our medicines to more people faster and in a more cost-efficient manner,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “Our commitment to innovation extends beyond our labs, and as a leading global oncology company with an ongoing mission to being a good corporate citizen, we know we must continue to do right not only by our patients, colleagues and stakeholders, but also the communities in which we operate.”

BeiGene’s Responsible Business & Sustainability strategy is centered around four pillars: Advancing Global Health, Empowering Our Colleagues, Innovating Sustainably, and Operating Responsibly. Beginning in 2021, BeiGene committed to setting goals for each of these pillars and reporting on progress annually.

Key Achievements

BeiGene’s Responsible Business & Sustainability Report highlights key achievements from 2023, including:

• Improved the percentage of women holding positions of Vice President and higher from 33% to 38% year over year.
• Established a global health equity strategy.
• Surpassed 20,000 hours of employee volunteerism worldwide.
• Integrated climate risk into our Enterprise Risk Management process.
• Launched a supplier engagement program, which will help enable BeiGene to set a Scope 3 target by 2025.

Setting First Quantitative Climate Goal